Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer called gastrointestinal neuroendocrine carcinoma (NEC), which includes a mix of NEC and other cancer cells (MiNEN with NEC). Other types of NET (neuroendocrine tumors) are not eligible.
- You should not have had any prior chemotherapy or targeted therapy for advanced or metastatic cancer. If you had chemo or chemoradiation for early-stage cancer (neoadjuvant/adjuvant), it must be at least 6 months since then and your cancer has now returned or spread.
- You must be physically active enough to perform everyday tasks without assistance (ECOG 0 or 1).
- Your blood cell counts and liver/kidney function need to be within certain limits (your doctor will check this).
- You cannot have an active autoimmune disease (like lupus, rheumatoid arthritis, Crohn's), active infections (like hepatitis B, C, HIV, or TB), or any history of lung disease like pulmonary fibrosis or interstitial pneumonia.
- Women and men must be willing to use effective contraception during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
This trial tests combining chemotherapy with an immunotherapy drug called durvalumab before and after surgery for stomach or lower esophagus cancer. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
Hear when a new Gastrointestinal Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.